Table 2.

Resume of cut-off values of prognostic factor for OMD in retrospective studies

Prognostic factors	Cut-off values	References	Outcomes
Size	Pulmonary metastasis: 30 mm	Fode et al. [13]	OS, LPFS
	OM-CRC: 20-30 mm	Franzese et al. [17]
		Sharma et al. [25]
		Nicosia et al. [26]
Number	1–5	Fode et al. [13]	OS, tPMC
	OM-CRC: 3	Franceschini et al. [14]
		Klement et al. [15]
		Ricardi et al. [16]
		Franzese et al. [17]
		Nicosia et al. [26]
Site	Lung metastasis	Franceschini et al. [14]	OS
	OM-PC: Bone only	Franzese et al. [17]
		Chen et al. [44]
DFI	Pulmonary metastasis: 30 months	Franzese et al. [17]	OS, PFS
	OM-PC: 24–34 months	Alongi et al. [35]
	OM-CRC: 30 months	Chen et al. [36]
	EP-OM other histologiesa: 24 months	Chen et al. [44]
Markers	OM-CRC: CEA < 100 ng/ml	Thompson et al. [32]	OS, PFS
	NSCLC: CTC clearance to ≤ 15/ml	Lebow et al. [34]
Prior systemic therapy	OM-CRC: < 2 line	Franzese et al. [17]	OS
		Thompson et al. [32]
		Klement et al. [40]
Primary site	Breast, prostate	Milano et al. [42]	OS
		Chen et al. [44]
PS	0–1	Fode et al. [13]	OS
		Yamamoto et al. [23]

OMD Oligometastatic-Disease, LPFS Local Progresison Free Survival, tPMC time to PolyMetastatic Conversion, DFI Disease-Free Interval, PS Performance Status, OM Oligometastatic, CRC Colorectal Cancer, PC Prostate Cancer, EP Extrapulmonary, CEA Carcinoembryonic Antigen, OS Overall Survival, PFS Progression-Free Survival

^aNSCLC, H&N, Breast triple negative, Melanoma, Sarcoma